FR2795415B1 - Compose peptidique derive d'une orf decalee du gene ice - Google Patents

Compose peptidique derive d'une orf decalee du gene ice

Info

Publication number
FR2795415B1
FR2795415B1 FR9908224A FR9908224A FR2795415B1 FR 2795415 B1 FR2795415 B1 FR 2795415B1 FR 9908224 A FR9908224 A FR 9908224A FR 9908224 A FR9908224 A FR 9908224A FR 2795415 B1 FR2795415 B1 FR 2795415B1
Authority
FR
France
Prior art keywords
peptide compound
orf
offset
compound derived
ice gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9908224A
Other languages
English (en)
French (fr)
Other versions
FR2795415A1 (fr
Inventor
Christophe Ronsin
Veronique Scott
Frederic Triebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Original Assignee
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9908224A priority Critical patent/FR2795415B1/fr
Application filed by Institut Gustave Roussy (IGR) filed Critical Institut Gustave Roussy (IGR)
Priority to DE60023891T priority patent/DE60023891T2/de
Priority to JP2001506778A priority patent/JP2003503042A/ja
Priority to PCT/FR2000/001791 priority patent/WO2001000784A2/fr
Priority to EP00946023A priority patent/EP1192179B1/fr
Priority to CA002377433A priority patent/CA2377433A1/fr
Priority to AU59925/00A priority patent/AU5992500A/en
Priority to US10/019,219 priority patent/US6875844B1/en
Priority to AT00946023T priority patent/ATE309265T1/de
Publication of FR2795415A1 publication Critical patent/FR2795415A1/fr
Application granted granted Critical
Publication of FR2795415B1 publication Critical patent/FR2795415B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9908224A 1999-06-28 1999-06-28 Compose peptidique derive d'une orf decalee du gene ice Expired - Fee Related FR2795415B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR9908224A FR2795415B1 (fr) 1999-06-28 1999-06-28 Compose peptidique derive d'une orf decalee du gene ice
JP2001506778A JP2003503042A (ja) 1999-06-28 2000-06-27 ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物
PCT/FR2000/001791 WO2001000784A2 (fr) 1999-06-28 2000-06-27 COMPOSE PEPTIDIQUE DERIVE D'UNE ORF DECALEE DU GENE iCE
EP00946023A EP1192179B1 (fr) 1999-06-28 2000-06-27 COMPOSE PEPTIDIQUE DERIVE D'UNE ORF DECALEE DU GENE iCE
DE60023891T DE60023891T2 (de) 1999-06-28 2000-06-27 Peptidverbindung, die von einem verschobenen offenen leserahmen des ice-gens abstammt
CA002377433A CA2377433A1 (fr) 1999-06-28 2000-06-27 Compose peptidique derive d'une orf decalee du gene ice
AU59925/00A AU5992500A (en) 1999-06-28 2000-06-27 Compound derived from an offset orf of the ice gene
US10/019,219 US6875844B1 (en) 1999-06-28 2000-06-27 Peptide compounds derived from a shifted ORF of the iCE gene
AT00946023T ATE309265T1 (de) 1999-06-28 2000-06-27 Peptidverbindung, die von einem verschobenen offenen leserahmen des ice-gens abstammt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9908224A FR2795415B1 (fr) 1999-06-28 1999-06-28 Compose peptidique derive d'une orf decalee du gene ice

Publications (2)

Publication Number Publication Date
FR2795415A1 FR2795415A1 (fr) 2000-12-29
FR2795415B1 true FR2795415B1 (fr) 2003-09-05

Family

ID=9547371

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9908224A Expired - Fee Related FR2795415B1 (fr) 1999-06-28 1999-06-28 Compose peptidique derive d'une orf decalee du gene ice

Country Status (9)

Country Link
US (1) US6875844B1 (https=)
EP (1) EP1192179B1 (https=)
JP (1) JP2003503042A (https=)
AT (1) ATE309265T1 (https=)
AU (1) AU5992500A (https=)
CA (1) CA2377433A1 (https=)
DE (1) DE60023891T2 (https=)
FR (1) FR2795415B1 (https=)
WO (1) WO2001000784A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7597894B2 (en) 2003-03-05 2009-10-06 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN104630149B (zh) * 2013-11-08 2018-08-21 中国科学院广州生物医药与健康研究院 外源线粒体导入到哺乳动物细胞中的方法
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2018035311A1 (en) * 2016-08-19 2018-02-22 Gray John T Compositions and methods for modulating gene expression using reading frame surveillance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
AU7724398A (en) * 1997-06-06 1998-12-21 Regents Of The University Of California, The A melanoma associated antigen, t cell epitopes thereof and methods of using sa me
AU9572098A (en) * 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel human cancer antigen ny eso-1/cag-3 and gene encoding same

Also Published As

Publication number Publication date
US6875844B1 (en) 2005-04-05
WO2001000784A3 (fr) 2001-07-26
EP1192179B1 (fr) 2005-11-09
AU5992500A (en) 2001-01-31
WO2001000784A2 (fr) 2001-01-04
FR2795415A1 (fr) 2000-12-29
DE60023891T2 (de) 2006-07-27
EP1192179A2 (fr) 2002-04-03
DE60023891D1 (de) 2005-12-15
JP2003503042A (ja) 2003-01-28
ATE309265T1 (de) 2005-11-15
CA2377433A1 (fr) 2001-01-04

Similar Documents

Publication Publication Date Title
EP1103564A4 (en) CANCER ANTIGEN, BASED ON TUMOR SUPPRESSIVE GENEVA PRODUCT WT1
AU4710499A (en) Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
WO2002008256A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
GB0129260D0 (en) Pharmaceutical compositions and their uses
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ATE254630T1 (de) Cyclosporine
AU4050801A (en) Intra-tumoral administration of il-12 encoding nucleic acid molecules
ATE259795T1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
PL342614A1 (en) Anticarcinogenic drugs
FR2795415B1 (fr) Compose peptidique derive d'une orf decalee du gene ice
DK1259536T3 (da) Fremgangsmåder til peptidfremstilling
DE69941877D1 (de) Neovaskular-spezifische peptide
NO20011817D0 (no) Ionebytte-tumormålsöking (IETT)
WO2001068676A3 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzeimittel
SG142165A1 (en) Biologically active peptides
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
WO2000052147A3 (en) Bacterial prolyl peptidases and methods of use
WO2000000509A3 (en) Peptides for inhibiting hpv e7 proteins
WO2003004064A3 (fr) Produits aptes a traiter les cancers de l'ovaire et a en prevenir les rechutes
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
ITMI922332A1 (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100226